Travere Therapeutics, Inc. Common Stock (TVTX) Stock
Key stats
- Market cap
- $5.00B
- Price / Earnings ratio
- -41.1x
- EPS (TTM)
- -$1.29
- Volume
- Loading
- 52-week high
- $68.73
- 52-week low
- $22.59
Source: third-party data provider, as of November 13, 2026
Compare with TVTX
Recent news

Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics to Participate at Upcoming Investor Conferences
TVTX

Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened
Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened
TVTX

Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
TVTX

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
TVTX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 48.47
- MACD 12/26/9
- -1.27
- EMA 9 of MACD
- -1.83
- MACD histogram
- 0.56
- SMA 50
- $56.56
- Price below SMA 50
- EMA 50
- $54.46
- Price below EMA 50
- SMA 200
- $47.49
- Price above SMA 200
- EMA 200
- $47.43
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.21 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Travere Therapeutics to Participate at Upcoming Investor Conferences
Travere Therapeutics to Participate at Upcoming Investor Conferences
TVTX

Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened
Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened
TVTX

Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings
TVTX

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call
TVTX

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
TVTX

Travere Therapeutics Reports Third Quarter 2026 Financial Results
Travere Therapeutics Reports Third Quarter 2026 Financial Results
TVTX

Travere Therapeutics to Report Third Quarter 2026 Financial Results
Travere Therapeutics to Report Third Quarter 2026 Financial Results
TVTX

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy
TVTX

Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline
Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline
TVTX

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TVTX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Travere Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Eric M. Dube Ph.D. | President, CEO & Director | 1973 |
| Mr. Christopher Cline C.F.A. | Chief Financial Officer | 1985 |
| Dr. William E. Rote Ph.D. | Chief Research Officer | 1963 |
| Mr. Peter Heerma | Chief Commercial Officer | 1971 |
| Dr. Jula Inrig M.D. | Executive VP, Head of Research & Development and Chief Medical Officer | 1975 |
| Ms. Sandra Calvin | SVP & Chief Accounting Officer | 1966 |
| Ms. Nivi Nehra | Vice President of Corporate Communications & Investor Relations | — |
| Ms. Elizabeth E. Reed J.D. | Chief Legal Officer, General Counsel & Secretary | 1971 |
| Ms. Angela Giannantonio | Chief People Officer | — |
| Mr. Casey Logan | Chief Business Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 48.47
- MACD 12/26/9
- -1.27
- EMA 9 of MACD
- -1.83
- MACD histogram
- 0.56
- SMA 50
- $56.56
- Price below SMA 50
- EMA 50
- $54.46
- Price below EMA 50
- SMA 200
- $47.49
- Price above SMA 200
- EMA 200
- $47.43
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $67.00
- Average
- $74.33
- High
- $86.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -2.8 | +10.9 | ||||||||||
| 2022 | -10.1 | +2.8 | -3.2 | -9.7 | -9.4 | +7.2 | -6.2 | +16.8 | -12.2 | -14.7 | -9.9 | +7.6 |
| 2023 | +8.4 | +0.3 | +3.4 | -4.2 | -20.9 | -15.6 | +10.5 | -14.6 | -39.9 | -23.0 | -6.5 | +40.0 |
| 2024 | -6.6 | -12.1 | -2.0 | -24.4 | +23.7 | +6.5 | +15.2 | +2.5 | +45.7 | +25.1 | +7.1 | -11.0 |
| 2025 | +7.9 | +5.8 | -9.5 | +19.3 | -27.6 | -4.6 | +5.0 | +12.0 | +31.7 | +41.8 | +2.5 | +8.6 |
| 2026 | -21.3 | -10.0 | +0.6 | +34.1 | +6.9 | +26.1 | -0.8 | +20.6 | -10.4 | -11.4 | +5.5 |



